Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorders of the complement ...

SIGN UP FOR THE FIELD & STREAM NEWSLETTER — Outdoor news, hunting and fishing tips, adventure stories, conservation issues—plus exclusive offers, giveaways, and more!